dactinomycin has been researched along with Hematologic Malignancies in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belka, C; Berdel, WE; Kreuter, M; Los, M; Renz, A; Schulze-Osthoff, K | 1 |
| Iguchi, A; Kaneda, M; Kobayashi, K; Kobayashi, R; Sato, T; Yasuda, K | 1 |
| Fujimoto, Y; Fujita, N; Ikawa, K; Ikeda, K; Kanbayashi, Y; Komori, T; Matsumoto, Y; Morikawa, N; Nomura, K; Shimazaki, C; Shimizu, D; Shimura, K; Taniguchi, K; Taniwaki, M | 1 |
| Aoki, K; Asano, S; Bessho, M; Fujita, A; Furusawa, S; Higashihara, M; Hirai, H; Hoshino, S; Hotta, T; Kitamura, K; Koike, M; Kuraishi, Y; Kurihara, I; Mizoguchi, H; Nagoshi, H; Nishimura, M; Nonaka, Y; Ohbayashi, Y; Omine, M; Oshimi, K; Ozawa, K; Suzuki, K; Takaku, F; Togawa, A; Urabe, A; Wakabayashi, Y | 1 |
| Bessho, M; Endo, K; Fukuda, M; Kawai, N; Maesaki, S; Takinami, S; Tominaga, K; Yamazaki, T | 1 |
4 trial(s) available for dactinomycin and Hematologic Malignancies
| Article | Year |
|---|---|
A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefozopran; Ceftazidime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Prospective Studies; Survival Rate | 2008 |
Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cefozopran; Cephalosporins; Female; Fever; Hematologic Neoplasms; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Monte Carlo Method; Neutropenia; Plasma | 2008 |
[Efficacy and safety of cefozopran (CZOP) monotherapy and combination therapy with CZOP and amikacin (AMK) for infections accompanying hematological diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cefozopran; Cephalosporins; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Immunocompromised Host; Male; Middle Aged; Pneumonia, Bacterial; Sepsis | 2000 |
[Clinical effects of combination therapy with cefozopran and amikacin for infections in patients with hematological disorders].
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cefozopran; Cephalosporins; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Immunocompromised Host; Male; Middle Aged; Opportunistic Infections; Treatment Outcome | 2001 |
1 other study(ies) available for dactinomycin and Hematologic Malignancies
| Article | Year |
|---|---|
Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo.
Topics: Adult; Aged; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Biomarkers; Biomarkers, Tumor; Chick Embryo; Cysteine Proteinase Inhibitors; Cytochrome c Group; Cytosol; Dactinomycin; Enzyme Inhibitors; Extracellular Space; Female; Hematologic Neoplasms; Humans; Hydrogen Peroxide; Jurkat Cells; L Cells; L-Lactate Dehydrogenase; Male; Mice; Middle Aged; Mitochondria; Necrosis; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; Protein Transport; Staurosporine; Tumor Necrosis Factor-alpha | 2001 |